Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (ASTARTÉ): protocol for a randomised, pragmatic trial
Guardado en:
Autores principales: | Clara M Rosso-Fernández, Pilar Retamar, Belén Gutiérrez-Gutiérrez, Alvaro Pascual, Elena Salamanca, Vicente Merino, Luis Eduardo López-Cortés, Alicia Marín-Candón, Natalia Bustos de Godoy, Lorena López-Cerero, Lydia Barrera Pulido, Irene Borreguero Borreguero, María José León, Manuel Camean-Fernández |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/505cc657de344c528b8d957a3dcaa1bc |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Real-world clinical outcomes of meropenem/vaborbactam for treatment of carbapenem-resistant Enterobacterales infections
por: Helen L. Zhang, et al.
Publicado: (2021) -
Epidemiology, risk factors, and prediction score of carbapenem resistance among inpatients colonized or infected with 3rd generation cephalosporin resistant Enterobacterales
por: Rima Moghnieh, et al.
Publicado: (2021) -
Bacteraemia by Achromobacter denitrificans in Hemodialysis
por: Venice Chavez-Valencia, et al.
Publicado: (2021) -
Risk factors and outcomes of Stenotrophomonas maltophilia bacteraemia: a comparison with bacteraemia caused by Pseudomonas aeruginosa and Acinetobacter species.
por: Go Hotta, et al.
Publicado: (2014) -
ANTIBIOTIC RESISTANCE OF KLEBSIELLA PNEUMONIAE TO CEPHALOSPORINS
por: E. V. Anganova, et al.
Publicado: (2017)